References

Cancer information / Cancer types / Breast / Treatment / Recurrent

08: Locoregional recurrence. BC Cancer Agency. (2004, November). Cancer Management Guidelines. Vancouver, BC: BC Cancer Agency.

10: Metastatic disease. BC Cancer Agency. (2006, August). Cancer Management Guidelines. Vancouver, BC: BC Cancer Agency.

Bursein HJ, Harris JR, Morrow M. Malignant tumors of the breast. Devita, V. T., Jr., Lawrence, T. S., & Rosenberg, S. A. (2008). Cancer: Principles & Practice of Oncology. (8th Edition). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 43.2: pp. 1606-54.

Cancer Care Ontario. Drug Formulary. Toronto, ON: Cancer Care Ontario.

Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. (2011, March 12). Lancet. New York, NY: Elsevier, Inc. 377(9769):914-23 (PMID: 21376385 ).

Dhesy-Thind B, Pritchard KI, Messersmith H, et al. The role of HER2/neu in systemic and radiation therapy for women with breast cancer: a clinical practice guideline. Cancer Care Ontario. (2006, November 10). Evidence-Based Series (EBS) and Practice Guidelines (PG). Toronto, ON: Cancer Care Ontario. Evidence-based Series #1-17: Section 1.

Flemming J, Madarnas Y, Franek J, and the Breast Cancer Disease Site Group. Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: guideline recommendations. Cancer Care Ontario. (2008, September 25). Evidence-Based Series (EBS) and Practice Guidelines (PG). Toronto, ON: Cancer Care Ontario. Evidence-based Series #1-13: Section 1.

Foxson SB, Lattimer JG & Felder B. Breast cancer. Yarbro, CH, Wujcki D, & Holmes Gobel B. (eds.). (2011). Cancer Nursing: Principles and Practice. (7th Edition). Sudbury, MA: Jones and Bartlett. 48: pp. 1091-1145.

Health Canada. (2013, 08/07). Drug and health products: Perjeta.

Health Canada. (2014, 01/06). Drug and health products: Kadcyla.

Bisphosphonates for secondary breast cancer. Macmillan Cancer Support. Macmillan Cancer Support. London, UK: Macmillan Cancer Support.

Members of the Breast Cancer Disease Site Group. The role of aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer. Program in Evidence-Based Care (PEBC), Cancer Care Ontario. (2003, October). Practice Guidelines and Evidence Summaries. Hamilton, ON: Cancer Care Ontario. Practice guideline report #1-5.

National Cancer Institute. (2010, August 13). Breast Cancer Treatment (PDQ®) Health Professional Version. Bethesda, MD: National Cancer Institute.

National Cancer Institute. (2010, September 9). Breast CancerTreatment (PDQ®) Patient Version. Bethesda, MD: National Cancer Institute.

Breast cancer. National Comprehensive Cancer Network. (2010). NCCN Clinical Practice Guidelines in Oncology. v.2.2010.

Shablak A. Eribulin for advanced breast cancer: a drug evaluation. (2013, March). Journal of Breast Cancer. Korean Breast Cancer Society. 16(1):12-15. (PMID: 23593076).

Warr D, Johnston M, and members of the Breast Cancer Disease Site Group. Use of bisphosphonates in women with breast cancer. Cancer Care Ontario. (2004, April). Practice Guidelines and Evidence Summaries. Hamilton, ON: Cancer Care Ontario. Practice Guideline Report #1-11 (Version 2.2002).

×
×